Group 1 - The core point of the news is that Shanghai Xuerong Biotechnology Co., Ltd. plans to establish a new subsidiary, Chengdu Xuesao Biotechnology Co., Ltd., to focus on the artificial cultivation and commercialization of Cordyceps, a species of national secondary protected plant [1] - Chengdu Xuesao will have a registered capital of 20 million yuan, with Xuerong contributing 10.2 million yuan (51%), Chenshi Biotechnology contributing 7 million yuan (35%), and Zheng Weidong contributing 2.8 million yuan (14%) [1] - The establishment of this subsidiary aligns with the company's strategy for diversified product offerings and aims to enhance production capacity utilization while reducing costs in the existing edible fungus business [1] Group 2 - Xuerong Biotechnology primarily engages in the research, industrial cultivation, and sales of fresh edible fungi [2] - In the first quarter of 2025, the company reported a revenue of 441 million yuan, a year-on-year decrease of 27.04%, while the net profit attributable to shareholders increased by 38.20% to 7.24 million yuan [2]

Group 1 - The company held its 30th meeting of the 5th board of directors, which was conducted both in-person and via electronic communication [1] - The board approved the establishment of Chengdu Xuecao Biotechnology Co., Ltd. in collaboration with Qinghai Chenxin Biotechnology Co., Ltd. and Mr. Zheng Weidong to enhance production capacity and optimize product structure [1][2] - Chengdu Xuecao will focus on the research, cultivation, and sales of Cordyceps sinensis, with a registered capital of 20 million yuan [2] Group 2 - Chengdu Xuelong will contribute 10.2 million yuan, accounting for 51% of the registered capital, while Chenxin Biotechnology will contribute 7 million yuan (35%) and Mr. Zheng Weidong will contribute 2.8 million yuan (14%) [2] - The investment proposal received unanimous approval from the board members, with 6 votes in favor and no opposition [2] - The company plans to apply for a credit facility of up to 1 billion yuan from China Construction Bank, with the decision also receiving unanimous support from the board [2]

Core Viewpoint - The company Snow Rong Bio announced the establishment of a new subsidiary, Chengdu Snow Grass Biotechnology Co., Ltd., in collaboration with Qinghai Chenxin Biotechnology Co., Ltd. and Mr. Zheng Weidong, focusing on the research, cultivation, and sales of Cordyceps sinensis, aligning with its multi-product strategy and aiming to enhance production capacity and reduce costs in its edible fungi business [1] Group 1 - Chengdu Snow Grass will have a registered capital of 20 million yuan, with Snow Rong Bio contributing 10.2 million yuan, accounting for 51% of the investment [1] - Qinghai Chenxin will contribute 7 million yuan in intangible assets, representing 35% of the investment [1] - Mr. Zheng Weidong will invest 2.8 million yuan, holding a 14% stake in the new company [1] Group 2 - The establishment of Chengdu Snow Grass is part of the company's strategy to diversify its product offerings and is expected to improve the utilization rate of existing production capacity [1] - This investment represents the company's attempt to venture into high-end products within the industry [1]

Core Viewpoint - Xuerong Biotechnology (300511.SZ) is establishing a new company, Chengdu Xuesao Biotechnology Co., Ltd., to enhance production capacity utilization and optimize product structure through a multi-variety layout strategy [1] Group 1: Company Investment and Structure - Chengdu Xuesao will be jointly funded by Chengdu Xuerong, Qinghai Chenxin Biotechnology Co., Ltd., and Mr. Zheng Weidong, with a registered capital of 20 million yuan [1] - Chengdu Xuerong will contribute 10.2 million yuan, holding a 51% stake, while Chenxin Biotechnology will contribute 7 million yuan for a 35% stake, and Mr. Zheng will invest 2.8 million yuan for a 14% stake [1] - The primary focus of Chengdu Xuesao will be on the research, cultivation, and sales of Cordyceps sinensis [1]